HomeCompareBIESF vs MCD

BIESF vs MCD: Dividend Comparison 2026

BIESF yields 0.15% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCD wins by $3.5K in total portfolio value
10 years
BIESF
BIESF
● Live price
0.15%
Share price
$32.00
Annual div
$0.05
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$75.0K
Annual income
$32,334.90
Full BIESF calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — BIESF vs MCD

📍 MCD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBIESFMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BIESF + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BIESF pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BIESF
Annual income on $10K today (after 15% tax)
$12.37/yr
After 10yr DRIP, annual income (after tax)
$27,484.67/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, BIESF beats the other by $5,191.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BIESF + MCD for your $10,000?

BIESF: 50%MCD: 50%
100% MCD50/50100% BIESF
Portfolio after 10yr
$76.8K
Annual income
$29,281.30/yr
Blended yield
38.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

BIESF
No analyst data
Altman Z
2.2
Piotroski
4/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BIESF buys
0
MCD buys
0
No recent congressional trades found for BIESF or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBIESFMCD
Forward yield0.15%2.35%
Annual dividend / share$0.05$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%42.3%
Portfolio after 10y$75.0K$78.5K
Annual income after 10y$32,334.90$26,227.70
Total dividends collected$52.6K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: BIESF vs MCD ($10,000, DRIP)

YearBIESF PortfolioBIESF Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$10,729$29.12$10,815$334.85$86.00MCD
2$11,539$58.39$11,826$491.71$287.00MCD
3$12,464$117.38$13,123$730.06$659.00MCD
4$13,573$236.99$14,853$1,100.07$1.3KMCD
5$15,006$482.41$17,257$1,690.61$2.3KMCD
6$17,053$996.86$20,752$2,667.01$3.7KMCD
7$20,364$2,117.50$26,103$4,354.83$5.7KMCD
8$26,516$4,726.47$34,794$7,437.78$8.3KMCD
9$39,876$11,503.41$49,926$13,461.60$10.1KMCD
10$75,002$32,334.90$78,550$26,227.70$3.5KMCD

BIESF vs MCD: Complete Analysis 2026

BIESFStock

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Full BIESF Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this BIESF vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BIESF vs SCHDBIESF vs JEPIBIESF vs OBIESF vs KOBIESF vs MAINBIESF vs YUMBIESF vs QSRBIESF vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.